Related News Items
New York Biotechnology Association to Honor Regeneron Founders as Business Leaders of the Year
Fri, 18 May 2012 05:45:00 -0700
New York Biotechnology Association , the voice of New York State’s bioscience industry, today announced that the 2012 honorees of the Association’s annual leadership awards will be the leaders of Regeneron Pharmaceuticals, New York’s largest biotechnology company: Dr.
Read More...
Spectrum Pharmaceuticals Commences Phase 2 Study of ZEVALIN® in Combination with the Redox Modulating Agent Motexafin ...
Thu, 17 May 2012 04:00:00 -0700
Spectrum Pharmaceuticals , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study evaluating ZEVALIN® Injection for intravenous use + rituximab in combination with motexafin gadolinium in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin ...
Read More...
Panel of Top Industry Executives to Discuss Biotech and Big Pharma – What’s Next? – 2012 BIO International Convention ...
Wed, 16 May 2012 13:54:00 -0700
The Biotechnology Industry Organization announced today that a panel of top industry executives will discuss where biotech will be in the next ten years and how the pharmaceutical industry landscape is changing.
Read More...
Infinity Added to NASDAQ Biotechnology Index
Tue, 15 May 2012 05:00:00 -0700
Infinity Pharmaceuticals, Inc. today announced that the company will be added to the NASDAQ Biotechnology Index® . The semi-annual re-ranking of the index will
Read More...
Avraham Pharmaceuticals Announces Commencement of a Phase 2 Study of Ladostigil for the Treatment of MCI
Thu, 17 May 2012 08:36:00 -0700
Avraham Pharmaceuticals Ltd. announced today the commencement of a Phase 2 clinical trial to evaluate the safety and efficacy of ladostigil in patients diagnosed with mild cognitive impairment .
Read More...
EnVivo Pharmaceuticals Names Christopher L. Burnley Chief Business Officer
Thu, 19 Apr 2012 05:30:00 -0700
EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system therapies, today announced that Christopher L. Burnley has been appointed chief business officer.
Read More...
Spectrum Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
Tue, 08 May 2012 04:00:00 -0700
Spectrum Pharmaceuticals , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today that an overview of the Company’s business strategy will be given at the Bank of America Merrill Lynch 2012 Health Care Conference being held at Encore at the Wynn Hotel in Las Vegas, Nevada.
Read More...
Spectrum Pharmaceuticals to Present at the Deutsche Bank 37th Annual Health Care Conference
Tue, 01 May 2012 04:00:00 -0700
Read More...
Partners List
Partners List